CSBTF (Kuros Biosciences) 1-Year Sharpe Ratio: -0.85 (As of Jul. 12, 2026)


CSBTF Kuros Biosciences Ltd CSBTF
72 GF Score
Price $25.57
GF Value $46.88
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Kuros Biosciences 1-Year Sharpe Ratio?

Kuros Biosciences CSBTF 72 1-Year Sharpe Ratio is -0.85 as of Jul. 12, 2026. GuruFocus rates CSBTF with a GF Score™ of 72/100 and a GF Value™ of $46.88 (Significantly Undervalued). The stock has 2 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-12), Kuros Biosciences's 1-Year Sharpe Ratio is -0.85.

Kuros Biosciences  (OTCPK:CSBTF) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Kuros Biosciences 1-Year Sharpe Ratio Related Terms

CSBTF vs ABT, SYK, MDT: 1-Year Sharpe Ratio Comparison

For the Medical Devices subindustry, Kuros Biosciences's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kuros Biosciences 1-Year Sharpe Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's 1-Year Sharpe Ratio falls into.


CSBTF
72GF Score
Kuros Biosciences Ltd CSBTF
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kuros Biosciences 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.85 mean?
Kuros Biosciences (CSBTF) has a 1-Year Sharpe Ratio of -0.85 as of Jul. 12, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Kuros Biosciences and its competitors.
Is Kuros Biosciences' 1-Year Sharpe Ratio too high?
Kuros Biosciences' current 1-Year Sharpe Ratio is -0.85. Overall, Kuros Biosciences has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' 1-Year Sharpe Ratio compare to ABT and SYK?
Kuros Biosciences' 1-Year Sharpe Ratio of -0.85 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Devices & Instruments company?
A good 1-Year Sharpe Ratio depends on the Medical Devices & Instruments industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Kuros Biosciences and its competitors. Kuros Biosciences's current 1-Year Sharpe Ratio is -0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $46.88, compared to a current price of $25.57 — trading 45.5% below its estimated fair value. The current 1-Year Sharpe Ratio is -0.85. Kuros Biosciences' overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current 1-Year Sharpe Ratio is -0.85 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kuros Biosciences (CSBTF) Overvalued in 2026?

Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued. The current stock price of $25.57 is trading 45.5% below its estimated GF Value™ of $46.88. GuruFocus considers Kuros Biosciences to be Significantly Undervalued.

Key valuation signals for CSBTF:

  • 1-Year Sharpe Ratio: -0.85
  • GF Value™: $46.88 vs. price of $25.57 (45.5% below fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kuros Biosciences Business Description

Address Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
72GF Score

Get the complete analysis for CSBTF

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.57
Price
$46.88
GF Value